Documentation and Transfer Process Clause Samples
Documentation and Transfer Process. In connection with the transfer of the Antibody Material as described in Section 6.1, the following shall apply:
(a) Novartis will share with Company any MSDSs and customs value information to the extent (i) readily available to Novartis (and not otherwise available to Company), and (ii) reasonably necessary to permit Company to pick up the Antibody Material in accordance with Applicable Law and this Agreement;
(b) Company will be solely responsible for any re-testing associated with the Antibody Material prior to use;
(c) with respect to any released Antibody Material, Novartis will provide the certificate of analysis associated with its release;
(d) Company will be responsible for all documentation, licenses, customs clearance, costs, etc. that are needed for and related to the pick-up, transport, and subsequent delivery of the Antibody Material to the first destination as designated by Company and thereafter;
(e) unless Novartis otherwise agrees in writing, the Antibody Material will not be picked up from any one location in more than one installment; and
(f) the Antibody Material made available by Novartis will only be used according to its specifications, including release specifications, and in accordance with Applicable Laws, and Novartis will have no further obligation with respect to the Antibody Material.
Documentation and Transfer Process. In connection with the transfer of the BGJ398 Material as described in Section 6.1, the following shall apply:
(a) Novartis will share with QED any MSDSs and customs value information that is readily available to Novartis (and not otherwise available to QED), in particular Compound-specific information, as is reasonably necessary to permit QED to pick up the BGJ398 Material;
(b) QED will be solely responsible for any re-testing associated with the BGJ398 Material prior to use;
(c) with respect to the released clinical study BGJ398 Material, Novartis will provide the certificate of analysis associated with its release;
(d) QED will be responsible for all documentation, licenses, customs clearance, costs, etc. that are needed for and related to the pick-up, transport, and subsequent delivery of the BGJ398 Material to the first destination as designated by QED;
(e) the BGJ398 Material will be picked up in not more than one installment;
(f) the BGJ398 Material made available by Novartis will only be used according to its specifications, especially release specifications, and in accordance with Applicable Laws, and Novartis will have no further obligation with respect to the BGJ398 Material, except with respect to providing any documentation relating to the BGJ398 pursuant to Section 4.1 and as otherwise set forth in this Section 6.3;
(g) prior to the BGJ398 Material being made available by Novartis, Novartis will provide QED with copies of any GMP certificates issued by Regulatory Authorities for the Novartis manufacturing facilities used for manufacturing the BGJ398 Material; and
(h) Novartis shall promptly notify QED of any notice received by a Regulatory Authority regarding regulatory actions of Novartis manufacturing facilities used for manufacturing the BGJ398 Material, where such action is related to the BGJ398 Material. Novartis shall provide QED with copies of specific correspondence relating to such regulatory action pertaining to BGJ398 and shall cooperate with the applicable Regulatory Authority, including by providing any requested documentation related to the BGJ398 Material directly to such Regulatory Authority.
Documentation and Transfer Process. [***]
(i) [***].
(ii) [***].
(iii) [***].
(iv) [***].
(v) [***].
Documentation and Transfer Process. In connection with the transfer of Gedeptin®, the following shall apply:
(i) PNP will share with GeoVax any Material Safety Data Sheets requested by GeoVax and reasonably available to PNP.
(ii) GeoVax will be solely responsible for any testing associated with the transferred material prior to use.
(iii) GeoVax will be responsible for all documentation, licenses, costs, etc. that are needed for and related to the continuing storage, pick-up, transport, and subsequent delivery of the transferred material to the location designated by GeoVax.
(iv) GeoVax shall be solely responsible for the production and sourcing of all Development and Commercial materials for Licensed Product after the Effective Date of this Assignment and License Agreement.
(v) GeoVax shall use reasonable commercial efforts to supply sufficient Gedeptin® material, at no cost, in support of ▇▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇’s work, including specifically, sufficient material for a fifteen-person breast cancer trial. GeoVax will also provide regulatory oversight, as required by the IND, to support the fifteen-person breast cancer trial.
(vi) GeoVax will not object to ▇▇. ▇▇▇▇▇▇▇▇ continuing scientific research pertaining to the Ad/PNP-F-araAMP Technology, submitting patent improvements pertaining to the Ad/PNP-F-araAMP Technology, writing and submitting grants concerning the Ad/PNP-F-araAMP Technology, and publishing articles concerning the Ad/PNP-F-araAMP Technology.
(vii) To the extent that PNP Controls any improvements pertaining to the Ad/PNP-F-araAMP Technology, GeoVax shall be granted, and is hereby granted, an exclusive, worldwide license, with the right to sublicense to such improvements. Such license under this Section 3.05(vii) shall be granted, and is hereby granted, subject to the terms of this Agreement, except that no additional upfront license fees shall be required.